title: [Psoriasis vulgaris exacerbated by imatinib therapy in chronic myelogenous leukemia].
abstract: Administration of imatinib exacerbated psoriasis vulgaris in a case of chronic myelogenous leukemia (CML). After the cessation of imatinib therapy, the psoriasis was alleviated. Upon readministration of imatinib, the psoriasis worsened despite the improvement of hematological and cytogenetic findings in the CML. Psoriasis is known to be an autoimmune skin disease characterized by Th1 cell-mediated hyperproliferation of keratinocytes, and the type 1 helper T (Th1) cell subset increased with imatinib therapy. Thus, the exacerbation of psoriasis was likely due to the increase in Th1 cells associated with imatinib therapy.
authors.affiliation: Division of Gastroenterology, Chitose City Hospital.
authors.forename: Ken-ichi
authors.initials: K
authors.lastname: Shimizu
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Kuroda
authors.forename: Masaya
authors.initials: M
authors.lastname: Kida
authors.forename: Hideki
authors.initials: H
authors.lastname: Watanabe
authors.forename: Sayaka
authors.initials: S
authors.lastname: Shirao
authors.forename: Takehide
authors.initials: T
authors.lastname: Akiyama
authors.forename: Akihito
authors.initials: A
authors.lastname: Fujimi
authors.forename: Ikuta
authors.initials: I
authors.lastname: Tanaka
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Sato
authors.forename: Takuya
authors.initials: T
authors.lastname: Matsunaga
authors.forename: Yoshiro
authors.initials: Y
authors.lastname: Niitsu
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011565:Psoriasis / Q000139:chemically induced* / Q000276:immunology; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D018417:Th1 Cells / Q000276:immunology
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate